{"entity":{"id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","aka":[],"tldr":"A phase 2/3 trial of Adagrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Mirati Therapeutics Inc., now recruiting.","summary":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 is a phase 2/3 interventional study registered as NCT04613596 by Mirati Therapeutics Inc., with 626 participants planned, started 2020-12-02 and due to reach its primary completion in 2028-10-31. Interventions recorded: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab. Conditions listed: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04613596","url":"https://clinicaltrials.gov/study/NCT04613596"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","kras-g12c-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","kras-inhibitors"],"targets":[],"drugs":["adagrasib","pembrolizumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04613596","phase":"2/3","setting":"A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","sponsor":"Mirati Therapeutics Inc.","participation":[{"nct":"NCT04613596","source":"https://clinicaltrials.gov/study/NCT04613596","fetchedAt":"2026-10-07T16:53:23.898Z","studySha256":"b1e0ea5ec716c0701c5eae451ee15f80e22de6a79457887171b2caac38497a05","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-16","leadSponsor":"Mirati Therapeutics Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":626,"enrolmentType":"ESTIMATED","siteCount":770,"recruitingSiteCount":378,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Romania","Serbia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2020-12-02","startedType":"actual","enrolled":626,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04613596/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}